Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients

International Immunopharmacology

Volumn 6, Issue 13-14, 2006, Pages 1977-1983

  Bilbao, Itxarone ^a   Castells, Luis ^a   Rojas, Luis ^a   Cancino, Jorge ^a   Dopazo, Cristina ^a   Castro, Ernest ^a   Pou, Leonor ^b   Andino, Ricardo ^a   Margarit, Carlos ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Conversion; Liver transplantation; Mycophenolate mofetil; Nephrotoxicity; Stable patients

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; UREA;

ADULT; AGED; ARTICLE; CENTRAL RETINA ARTERY OCCLUSION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART FAILURE; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UREA BLOOD LEVEL;

AGED; CALCINEURIN; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UREA;

EID: 33845211677     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.09.022     Document Type: Article

References (18)

1. Gonwa T.A., Mai M.L., Melton L.B., Hays S.R., Goldstein R.M., Levy M.F., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy and risk of development and treatment. Transplantation 72 12 (2001) 1934-1939
2. Danovitch G.M. Immunosuppressant-induced metabolic toxicities. Transplant Rev 14 2 (2000) 65-81
3. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 10 (2003) 931-940
4. Paramesh A.S., Roayale S., Doan Y., Schwartz M.E., Emre S., Fishbein T., et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 18 (2004) 94
5. Lipsky J.L. Mycophenolate mofetil. Lancet 348 (1996) 1357
6. Finzi D., and Siciliano R.F. Taking aim at HIV replication. Nat Med 6 (2000) 735-736
7. Meier-Kriesche H.U., Shaw L.M., Korecka M., and Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 22 (2000) 27-30
8. Pisupati J., Jain A., Burckart G., Hamad I., Zuckerman S., Fung J., et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 45 1 (2005) 34-41
9. Bilbao I., Castells L., Murio E., Lazaro J., Escartin A., Solans A., et al. Late morbimortality in liver transplantation. Poster Presented in the "9th Congress of the International Liver Transplantation Society (ILTS). 13th Congress of the Liver Intensive Care Group of Europe (LICAGE)". Barcelona June 18-21 (2003)
10. Koch R.O., Graziadei I.W., Schutz F., Nachbaur K., Königsrainer A., Margreiter R., et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 17 9 (2004) 518-524
11. Moreno J.M., Cuervas-Mons V., Rubio E., Gomez A., Lopez-Monclus J., Sanchez-Turrion V., et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 4 (2004) 1650-1655
12. Schlitt H.J., Barkmann A., Böker K.K., Schmidt H.H., Emmanouilidis N., Rosenau J., et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 357 (2001) 587-591
13. Pierini A., Mirabella S., Brunati A., Richiuti A., Franchello A., and Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 37 6 (2005) 2614-2615
14. Beckebaum S., Cicinnati V.R., Klein C.G., Brokalaki E., Yu Z., Malago M., et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 36 9 (2004) 2671-2674
15. Steward S.F., Hudson M., Talbot D., Manas D., and Day C.P. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 357 9256 (2001) 609-610
16. Fairbanks K.D., and Thuluvath P.J. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transplant 10 9 (2004) 1189-1194
17. Reich D.J., Clavien P.A., and Hodge E.E. MMF renal dysfunction after liver transplantation working group. Transplantation 80 1 (2005) 18-25
18. Hong M.K., Angus P.W., Jones R.M., Vaughan R.B., and Gow P.J. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant 19 2 (2005) 193-198